vs
Celldex Therapeutics, Inc.（CLDX）与Alpha Teknova, Inc.（TKNO）财务数据对比。点击上方公司名可切换其他公司
Alpha Teknova, Inc.的季度营收约是Celldex Therapeutics, Inc.的83.2倍（$10.0M vs $120.0K）。Alpha Teknova, Inc.净利率更高（-47.7% vs -67764.2%，领先67716.5%）。Alpha Teknova, Inc.同比增速更快（7.8% vs -89.8%）。Alpha Teknova, Inc.自由现金流更多（$-810.0K vs $-65.2M）。过去两年Alpha Teknova, Inc.的营收复合增速更高（3.7% vs -12.3%）
Celldex Therapeutics是一家临床阶段生物制药企业，专注于开发针对难治性癌症和罕见免疫疾病的靶向免疫疗法，管线涵盖抗体药物偶联物、单克隆抗体等创新疗法，致力于满足大量未被满足的临床医疗需求。
Alpha Teknova, Inc.是一家生命科学企业，研发并生产专用试剂、细胞培养基及定制实验室解决方案，服务生物制药、分子诊断及学术研究领域客户，主要面向北美市场，为药物研发、诊断测试及生命科学研究流程提供支持。
CLDX vs TKNO — 直观对比
营收规模更大
TKNO
是对方的83.2倍
$120.0K
营收增速更快
TKNO
高出97.5%
-89.8%
净利率更高
TKNO
高出67716.5%
-67764.2%
自由现金流更多
TKNO
多$64.4M
$-65.2M
两年增速更快
TKNO
近两年复合增速
-12.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $120.0K | $10.0M |
| 净利润 | $-81.3M | $-4.8M |
| 毛利率 | — | 32.5% |
| 营业利润率 | -72628.3% | -46.2% |
| 净利率 | -67764.2% | -47.7% |
| 营收同比 | -89.8% | 7.8% |
| 净利润同比 | -72.7% | 16.8% |
| 每股收益（稀释后） | $-1.23 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLDXTKNO
| Q4 25 | $120.0K | $10.0M | ||
| Q3 25 | $0 | $10.5M | ||
| Q2 25 | $730.0K | $10.3M | ||
| Q1 25 | $695.0K | $9.8M | ||
| Q4 24 | $1.2M | $9.3M | ||
| Q3 24 | $3.2M | $9.6M | ||
| Q2 24 | $2.5M | $9.6M | ||
| Q1 24 | $156.0K | $9.3M |
净利润CLDXTKNO
| Q4 25 | $-81.3M | $-4.8M | ||
| Q3 25 | $-67.0M | $-4.3M | ||
| Q2 25 | $-56.6M | $-3.6M | ||
| Q1 25 | $-53.8M | $-4.6M | ||
| Q4 24 | $-47.1M | $-5.7M | ||
| Q3 24 | $-42.1M | $-7.6M | ||
| Q2 24 | $-35.8M | $-5.4M | ||
| Q1 24 | $-32.8M | $-8.1M |
毛利率CLDXTKNO
| Q4 25 | — | 32.5% | ||
| Q3 25 | — | 30.7% | ||
| Q2 25 | — | 38.7% | ||
| Q1 25 | — | 30.7% | ||
| Q4 24 | — | 23.0% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 29.2% | ||
| Q1 24 | — | 23.8% |
营业利润率CLDXTKNO
| Q4 25 | -72628.3% | -46.2% | ||
| Q3 25 | — | -38.4% | ||
| Q2 25 | -8747.5% | -32.9% | ||
| Q1 25 | -9027.2% | -50.7% | ||
| Q4 24 | -4768.3% | -60.7% | ||
| Q3 24 | -1633.5% | -77.6% | ||
| Q2 24 | -1854.2% | -53.0% | ||
| Q1 24 | -26030.8% | -86.0% |
净利率CLDXTKNO
| Q4 25 | -67764.2% | -47.7% | ||
| Q3 25 | — | -41.0% | ||
| Q2 25 | -7753.4% | -34.7% | ||
| Q1 25 | -7740.4% | -47.4% | ||
| Q4 24 | -4007.8% | -61.7% | ||
| Q3 24 | -1320.0% | -79.0% | ||
| Q2 24 | -1434.8% | -55.8% | ||
| Q1 24 | -21030.8% | -87.2% |
每股收益（稀释后）CLDXTKNO
| Q4 25 | $-1.23 | $-0.08 | ||
| Q3 25 | $-1.01 | $-0.08 | ||
| Q2 25 | $-0.85 | $-0.07 | ||
| Q1 25 | $-0.81 | $-0.09 | ||
| Q4 24 | $-0.71 | $-0.09 | ||
| Q3 24 | $-0.64 | $-0.15 | ||
| Q2 24 | $-0.54 | $-0.13 | ||
| Q1 24 | $-0.56 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $518.6M | $21.3M |
| 总债务越低越好 | — | $13.1M |
| 股东权益账面价值 | $527.2M | $68.8M |
| 总资产 | $583.0M | $103.6M |
| 负债/权益比越低杠杆越低 | — | 0.19× |
8季度趋势，按日历期对齐
现金及短期投资CLDXTKNO
| Q4 25 | $518.6M | $21.3M | ||
| Q3 25 | $583.2M | $22.1M | ||
| Q2 25 | $630.3M | $24.0M | ||
| Q1 25 | $673.3M | $26.3M | ||
| Q4 24 | $725.3M | $30.4M | ||
| Q3 24 | $756.0M | $31.7M | ||
| Q2 24 | $802.3M | $18.6M | ||
| Q1 24 | $823.8M | $21.6M |
总债务CLDXTKNO
| Q4 25 | — | $13.1M | ||
| Q3 25 | — | $13.1M | ||
| Q2 25 | — | $13.0M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $12.3M | ||
| Q1 24 | — | $13.2M |
股东权益CLDXTKNO
| Q4 25 | $527.2M | $68.8M | ||
| Q3 25 | $598.4M | $72.7M | ||
| Q2 25 | $655.4M | $76.1M | ||
| Q1 25 | $703.0M | $78.6M | ||
| Q4 24 | $747.0M | $82.4M | ||
| Q3 24 | $785.9M | $87.3M | ||
| Q2 24 | $813.7M | $78.9M | ||
| Q1 24 | $838.6M | $83.4M |
总资产CLDXTKNO
| Q4 25 | $583.0M | $103.6M | ||
| Q3 25 | $648.4M | $107.6M | ||
| Q2 25 | $692.4M | $110.5M | ||
| Q1 25 | $739.5M | $114.0M | ||
| Q4 24 | $792.3M | $118.8M | ||
| Q3 24 | $823.2M | $124.1M | ||
| Q2 24 | $845.6M | $115.4M | ||
| Q1 24 | $868.8M | $120.8M |
负债/权益比CLDXTKNO
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-63.9M | $-462.0K |
| 自由现金流经营现金流 - 资本支出 | $-65.2M | $-810.0K |
| 自由现金流率自由现金流/营收 | -54350.8% | -8.1% |
| 资本支出强度资本支出/营收 | 1067.5% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-213.7M | $-9.8M |
8季度趋势，按日历期对齐
经营现金流CLDXTKNO
| Q4 25 | $-63.9M | $-462.0K | ||
| Q3 25 | $-48.6M | $-2.0M | ||
| Q2 25 | $-44.0M | $-2.1M | ||
| Q1 25 | $-54.4M | $-4.1M | ||
| Q4 24 | $-32.5M | $-936.0K | ||
| Q3 24 | $-55.3M | $-2.1M | ||
| Q2 24 | $-29.3M | $-2.8M | ||
| Q1 24 | $-40.6M | $-6.6M |
自由现金流CLDXTKNO
| Q4 25 | $-65.2M | $-810.0K | ||
| Q3 25 | $-49.1M | $-2.4M | ||
| Q2 25 | $-44.7M | $-2.3M | ||
| Q1 25 | $-54.6M | $-4.3M | ||
| Q4 24 | $-33.2M | $-1.5M | ||
| Q3 24 | $-55.9M | $-2.4M | ||
| Q2 24 | $-29.6M | $-3.0M | ||
| Q1 24 | $-41.0M | $-6.7M |
自由现金流率CLDXTKNO
| Q4 25 | -54350.8% | -8.1% | ||
| Q3 25 | — | -22.6% | ||
| Q2 25 | -6127.8% | -22.4% | ||
| Q1 25 | -7861.4% | -44.0% | ||
| Q4 24 | -2828.3% | -16.2% | ||
| Q3 24 | -1751.2% | -25.0% | ||
| Q2 24 | -1185.0% | -30.7% | ||
| Q1 24 | -26270.5% | -71.8% |
资本支出强度CLDXTKNO
| Q4 25 | 1067.5% | 3.5% | ||
| Q3 25 | — | 3.7% | ||
| Q2 25 | 99.7% | 2.0% | ||
| Q1 25 | 38.1% | 2.1% | ||
| Q4 24 | 64.3% | 6.1% | ||
| Q3 24 | 17.1% | 3.5% | ||
| Q2 24 | 11.0% | 1.2% | ||
| Q1 24 | 220.5% | 1.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLDX
暂无分部数据
TKNO
| Lab Essentials | $6.8M | 68% |
| Clinical Solutions | $2.7M | 27% |
| Other | $435.0K | 4% |
